NASDAQ:PAVM - PAVmed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.05 -0.01 (-0.94 %)
(As of 03/18/2019 04:00 PM ET)
Previous Close$1.06
Today's Range$1.04 - $1.08
52-Week Range$0.86 - $1.81
Volume204,200 shs
Average Volume195,633 shs
Market Capitalization$28.50 million
P/E Ratio-2.02
Dividend YieldN/A
Beta0.01
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAVM
CUSIPN/A
Phone212-949-4319

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.22) per share

Profitability

Net Income$-9,510,000.00

Miscellaneous

Employees3
Market Cap$28.50 million
Next Earnings Date4/10/2019 (Estimated)
OptionableNot Optionable

PAVmed (NASDAQ:PAVM) Frequently Asked Questions

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

How were PAVmed's earnings last quarter?

PAVmed Inc (NASDAQ:PAVM) released its quarterly earnings data on Thursday, November, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.04. View PAVmed's Earnings History.

When is PAVmed's next earnings date?

PAVmed is scheduled to release their next quarterly earnings announcement on Wednesday, April 10th 2019. View Earnings Estimates for PAVmed.

What price target have analysts set for PAVM?

1 brokerages have issued 12-month price objectives for PAVmed's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate PAVmed's stock price to reach $3.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Price Targets for PAVmed.

What is the consensus analysts' recommendation for PAVmed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

What are Wall Street analysts saying about PAVmed stock?

Here are some recent quotes from research analysts about PAVmed stock:
  • 1. Maxim Group analysts commented, "On 1/7/19, the FDA held a pre-submission meeting with PAVM and recommended the company conduct human clinical studies for CarpX to address any remaining substantial equivalence (SE) issues. PAVM intends to utilize its first-in-human (FIH) clinical study in a second site to satisfy the FDA’s requirements in support of a 510(k) resubmission. CarpX timeline being pushed out, we have lowered our estimates and price target to $3, from $4." (1/14/2019)
  • 2. According to Zacks Investment Research, "PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City. " (9/12/2018)

Has PAVmed been receiving favorable news coverage?

News coverage about PAVM stock has trended somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PAVmed earned a news impact score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are some of PAVmed's key competitors?

What other stocks do shareholders of PAVmed own?

Who are PAVmed's key executives?

PAVmed's management team includes the folowing people:
  • Dr. Lishan Aklog M.D., Chairman & CEO (Age 53)
  • Mr. Dennis M. McGrath CPA, Exec. VP, CFO & Sec. (Age 62)
  • Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 54)
  • Mr. Shaun M. O'Neil, Chief Commercial Officer

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $1.05.

How big of a company is PAVmed?

PAVmed has a market capitalization of $28.50 million. The company earns $-9,510,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. PAVmed employs 3 workers across the globe.

What is PAVmed's official website?

The official website for PAVmed is http://www.pavmed.com.

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]


MarketBeat Community Rating for PAVmed (NASDAQ PAVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe PAVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel